Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P000027/S044

Elecsys free PSA assay

Roche Diagnostics Corp. · Decision date Feb 27, 2026

FDA DECISIONP000027/S044

What did the FDA decide?

FDA records P000027/S044 as a supplement to PMA P000027, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 27, 2026.

FDA approval order statement

To add another location for a process within the same establishment.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Immunology
Decision date
Feb 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P000027/S044
Regulatory pathway
PMA supplement
Product code
LTJ
Decision code
OK30
Decision date
Feb 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS.

Product code
LTJ
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P000027/S044 received

    Application receipt date recorded by FDA.

  2. P000027/S044 · FDA decision

    30-Day Notice

  3. P000027/S045 · Related supplement

    ELECSYS FREE PSA IMMUNOASSAY/CALSET/CALCHECK

Timeline entries are records held by MedtechLedger for P000027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000027

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Diagnostics Corp.PMA supplementApr 29, 2026FDA

Explore the linked device profile

Other records with product code LTJ

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.510(k) clearanceJan 5, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Diagnostics Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9115 Hague Rd., Indianapolis, IN, 46250

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records